- Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Anastrozole; Drug: Placebo
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo; Procedure: quality-of-life assessment; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsors: Ohio State University Comprehensive Cancer Center; Maryam Lustberg; Cancer and Leukemia Group B; Alliance
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Neoplasm
Intervention: Drug: Pazopanib
Sponsors: University of California, San Francisco; Hope Rugo, MD; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: goserelin acetate; Drug: letrozole; Drug: anastrozole; Procedure: therapeutic conventional surgery; Genetic: DNA analysis; Other: immunohistochemistry staining method; Procedure: positron emission tomography; Genetic: comparative genomic hybridization; Procedure: biopsy; Other: laboratory biomarker analysis; Drug: chemotherapy
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: anastrozole; Drug: exemestane; Drug: fulvestrant; Drug: letrozole
Sponsors: National Cancer Institute (NCI); Washington University Siteman Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: entinostat; Drug: tamoxifen citrate; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified January 2011 - Condition: Idiopathic Short Stature
Interventions: Drug: Anastrozole and Letrozole; Drug: Somatropin; Drug: Aromatase inhibitor and somatropin
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; Thrasher Research Fund; Genentech; Novartis; AstraZeneca
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Anastrozole; Drug: ADZ0530; Drug: Placebo; Procedure: Pharmacokinetic studies; Procedure: Definitive Surgery; Procedure: Core Biopsy; Genetic: Tumor Tissue Collection for Genetic and Molecular Studies
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center; Doris Duke Charitable Foundation
Recruiting - verified October 2011 - Condition: Healthy Males
Interventions: Drug: Acyline; Drug: Testosterone gel applied transdermally for 10 days; Drug: ketoconazole; Drug: Ketoconazole; Drug: Dutasteride; Drug: Anastrozole
Sponsors: University of Washington; University of Washington; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Solid Tumors; Advanced Cancer
Interventions: Drug: Anastrozole; Drug: Bevacizumab; Drug: Everolimus; Drug: Sorafenib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: biopsy; Radiation: F-18 16 alpha-fluoroestradiol; Procedure: positron emission tomography; Drug: anastrozole; Drug: letrozole; Drug: exemestane; Genetic: gene expression analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Atrophic Vaginitis; Breast Cancer
Intervention: Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Conditions: Advanced Non-small Cell Lung Cancer; Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex); Drug: anastrozole (Arimidex); Drug: Bevacizumab (Avastin); Drug: Best standard of care
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012 - Condition: Invasive Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Anastrazole
Sponsors: University of Kansas; University of Kansas; AstraZeneca
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Procedure: assessment of therapy complications
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Arimidex with Faslodex; Drug: Arimidex without Faslodex
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; AstraZeneca
Recruiting - verified January 2012 - Conditions: Obesity; Oligospermia
Interventions: Drug: Anastrozole; Drug: Placebo
Sponsors: University of Utah; University of Utah
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011 - Condition: Healthy Volunteers
Interventions: Drug: Testosterone; Drug: Testosterone; Drug: Anastrazole; Drug: Goserelin acetate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute on Aging (NIA); Solvay Pharmaceuticals; AstraZeneca
Recruiting - verified April 2012
 |
Anastrozole Clinical Trials |
